S-EPMC8251553 - Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m<sup>2</sup> ) in combination with lenalidomide and dexamethasone. - OmicsDI

Unknown

Dataset Information

Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m² ) in combination with lenalidomide and dexamethasone.

ABSTRACT:

SUBMITTER: Korde N

PROVIDER: S-EPMC8251553 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature